The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis

Clinica Chimica Acta

Volumn 446, Issue , 2015, Pages 248-252

  Jing, Xiao Dong ^a   Wei, Xiao Ming ^a   Deng, Song Bai ^a   Du, Jian Lin ^a   Liu, Ya Jie ^a   She, Qiang ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

High density lipoprotein; In stent restenosis; Inflammation; Sphingosine 1 phosphate

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SPHINGOSINE 1 PHOSPHATE; BIOLOGICAL MARKER; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; LOGISTIC REGRESSION ANALYSIS; MALE; MULTIVARIATE STEPWISE LOGISTIC REGRESSION ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING; STENT LENGTH; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; STATISTICAL MODEL; STENT;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FEMALE; HUMANS; LIPOPROTEINS, HDL; LOGISTIC MODELS; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; RISK FACTORS; ROC CURVE; SPHINGOSINE; STENTS;

EID: 84929083381     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.04.038     Document Type: Article

References (20)

1. Bennett M.R. In-stent restenosis: pathology and implications for the development of drug-eluting sent. Heart 2003, 89:218-224.
2. Dehmer G.J., Smith K.J. Drug eluting coronary artery stents. Am Fam Physician 2009, 80:1245-1251.
3. Paudel B., Xuan G., Chun Z. Analysis of clinical factors affecting the restenosis following percutaneous coronary intervention. Nepal Med Coll J 2005, 7:101-106.
4. Guildford A.L., Stewart H.J., Morris C., Santin M. Substrate-induced phenotypic switches of human smooth cells: an in vitro study of in-stent restenosis activation pathways. J R Soc Interface 2011, 8:641-649.
5. Levade T., Auge N., Jan Veldman R.J., Cuvillier O., Negre-Salvayre A., Salvayre B. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ Res 2001, 89:957-968.
6. Allende M.L., Yamashita T., Proia R.L. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 2003, 3:665-667.
7. Murata N., Sato K., Kon J., Tomura H., Yanagita M., Kuwabara A., et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000, 352:809-815.
8. Xia P., Vadas M.A., Rye K.A., Barter P.J., Gamble J.R. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. J Biol Chem 1999, 274:33143-33147.
9. Deutschman D.H., Carstens J.S., Klepper R.L., Smith W.S., Page M.T., Young T.R., et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 2003, 146:62-68.
10. Sattler K.J., Elbasan S., Keul P., Elter-Schulz M., Bode C., Graler M.H., et al. Sphingosine-1-phosphate levels in plasma and HDL are altered in coronary disease. Basic Res Cardiol 2010, 105:821-823.
11. Kang S.J., Mintz G.S., Park D.W., Lee S.W., Kim Y.H., Whan Lee C., et al. Mechanisms of in-stent restenosis after drug-eluting stent implantation intravascular ultrasound analysis. Circ Cardiovasc 2011, 4:9-14.
12. Nofer J.R., Giet M., Tolle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004, 113:569-581.
13. Lan T., Bi H., Liu W., Xie X., Xu S., Huang H. Simultaneous determination of sphingosine and sphingosine 1-phosphate in biological samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2011, 879:520-525.
14. Tamama K., Tomura H., Sato K., Malchinkhuu E., Damirin A., Kimura T., et al. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis 2005, 178:19-23.
15. Pitson S.M., Pebay A. Regulatin of stem cell pluripotency and neural differentiation by lysophospholipids. Neurosignals 2009, 17:242-254.
16. Argraves K.M., Gazzolo P.J., Groh E.M., Wilkerson B.A., Matsuura B.S., Twal W.O., et al. High density lipoprotein-associated sphingosine-1-phosphate promotes endothelial barrier function. Biochemistry 2008, 283:25074-25081.
17. Pchejetski D., Kunduzova O., Dayon A., Calise D., Seguelas M.H., Leducq N., et al. Oxidative-stress dependent sphingosine kinase-1inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 2007, 100:41-49.
18. Versaci F., Gaspardone G. Prevention of restenosis after stenting: the emerging role of inflammation. Coron Artery Dis 2004, 15:307-311.
19. Moses J.W., Stone G.W., Nikolsky E., Mintz G.S., Dangas G., Grube E., et al. Drug-eluting stents in the treatment of intermediate lesions pooled analysis from four randomized trails. J Am Coll 2006, 2164-2171.
20. Stolker J.M., Kennedy K.F., Lindsey J.B., Marso S.P., Pencina M.J., Cutlip D.E., et al. Predicting restenosis of drug-eluting stents placed in real-world clinical practice derivation and validation of a risk model from the EVENT registry. Cardiovasc Interv 2010, 3:327-334.